Research
Hormonal
GLP-1RA therapy can reduce the risk of cardiovascular disease (CVD) in high-risk individuals with type 2 diabetes (T2D).
Practitioners should consider GLP-1RA therapy for patients with T2D who are at high risk for cardiovascular disease.
StrongSupportsmedium confidence
Large-scale randomized controlled cardiovascular (CV) outcome trials (CVOTs) have shown that GLP-1RA therapy can reduce the risk of CV disease (CVD) in high-risk individuals with T2D.
Why this rating
Based on large-scale randomized controlled trials.
Source
Understanding the place for <scp>GLP‐1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Christine R. Andreasen et al. · Diabetes Obesity and Metabolism · 2021
reviewCited 36×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →